Form 4 · Filed Jun 5, 2026, 09:03 PM UTC
RXRX/RECURSION PHARMACEUTICALS, INC.
Gibson Christopher — director
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
3 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | C | other | 40,000 | $0 | — | 923,735 |
| Jun 5, 2026 | S | sell | 40,000 | $4 | $144,800 | 883,735 |
| Jun 5, 2026 | C | other | 40,000 | — | — | 4,263,334 |
Source: SEC EDGAR raw filing ↗ · Accession 0001856369-26-000023